Octagon Capital Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Octagon Capital Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,551,703	Closed	-$59.1M	–	47
2023 Q1	$59.1M	Hold	2,551,703	–	–	8.52%	2
2022 Q4	$66.9M	Hold	2,551,703	–	–	10.41%	2
2022 Q3	$50.2M	Hold	2,551,703	–	–	8.66%	3
2022 Q2	$44.6M	Buy	2,551,703 +1,195,453	+88%	+$18.8M	11.91%	3
2022 Q1	$22.2M	Buy	1,356,250 +856,250	+171%	+$11.6M	4.8%	7
2021 Q4	$8.15M	Buy	+500,000	New	+$7.12M	1.59%	15

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return

Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return